Original manuscript

Autophagy During Left Ventricular Redilation After Ventriculoplasty: Insights from a Rat Model of Ischemic Cardiomyopathy

Satoshi Sugimoto, M.D.[1], Yasushige Shingu, M.D., Ph.D.[1], Torsten Doenst, M.D., Ph.D.[2], Tomoji Yamakawa, M.D.[3], Hidetsugu Asai, M.D., Ph.D.[4], Satoru Wakasa, M.D., Ph.D.[1], and Yoshiro Matsui, M.D., Ph.D.[1]

1. Department of Cardiovascular and Thoracic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
2. Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich Schiller University of Jena, Jena, Germany
3. Department of Cardiovascular Surgery, Kinikyo Chuo Hospital, Sapporo, Japan
4. Department of Cardiovascular Surgery, Kanagawa Children's Medical Center, Yokohama, Japan

Conflicts of interest: none.

Funding: Research grants from The Uehara Memorial Foundation and Sanofi

Address for correspondence:

Yasushige Shingu, M.D., Ph.D.

Department of Cardiovascular and Thoracic Surgery

Faculty of Medicine and Graduate School of Medicine, Hokkaido University

Kita 15, Nishi 7, Kitaku, Sapporo, 060-8638

Japan

Tel: +81-11-716-1161 (ext. 6042)

Fax: +81-11-706-7612

Email: shingu@huhp.hokudai.ac.jp

Word count: abstract, 219; manuscript, 3462; 19 references, 5 figures and 2 tables

30 **Glossary of Abbreviations**

31	αMHC	α myosin heavy chain
32	βMHC	β myosin heavy chain
33	BNP	brain natriuretic peptide
34	CI	cardiac index
35	FS	fractional shortening
36	LAD	left anterior descending artery
37	LC3	microtubule-associated protein light chain 3
38	LVDd	LV end-diastolic dimension
39	LVP	left ventriculoplasty
40	MI	myocardial infarction
41	3-MA	3-methyladenine

Abstract

Objectives: Myocardial autophagy has been recognized as an important factor in heart failure. It is not known whether changes in ventricular geometry by left ventriculoplasty influence autophagy in ischemic cardiomyopathy. We hypothesized that myocardial autophagy plays an important role in left ventricular (LV) redilation after ventriculoplasty.

Methods: Four weeks after ligation of the left anterior descending artery, ventriculoplasty or sham operation was performed. The animals were euthanized at 2 days (early) or 28 days (late) after the second operation. Ventricular autophagy was evaluated by protein expression of microtubule-associated protein light chain 3 (LC3) II, an autophagosome marker. Cardiomyocyte area was assessed by histological examination. LV function was evaluated by echocardiography. To examine the implications of autophagy, an autophagy inhibitor (3-methyladenine) was injected intraperitoneally for 3 weeks before sacrifice.

Results: The LV was reduced in size early and redilated late after ventriculoplasty. LV systolic function was improved early and later worsened after ventriculoplasty. LC3-II expression decreased early after ventriculoplasty and increased in the late period. Myocyte area increased from the early to late stage after ventriculoplasty. Autophagic inhibition exaggerated the increased myocyte hypertrophy and LV redilation.

Conclusions: In a rat model of myocardial infarction, autophagy decreased early after ventriculoplasty and increased again during LV redilation. These results provide new insights into the mechanism underlying the late failure of ventriculoplasty.

Central Picture Legend

Change in myocardial autophagy after left ventriculoplasty for ischemic cardiomyopathy.

Central Message

Myocardial autophagy decreases early after left ventriculoplasty and increases again during ventricular redilation, which might be one of the mechanisms for late failure of ventriculoplasty.

Perspective Statement

After left ventriculoplasty, myocardial autophagy decreases early and increases again during ventricular redilation, as an adaptive mechanism. Further studies are necessary to examine whether pharmacological interventions can modulate myocardial autophagy and maintain the early unloading effect of left ventriculoplasty in ischemic cardiomyopathy.

77 **Introduction**

78 Two main effects of left ventriculoplasty (LVP) have been described: reduction of LV
79 volume and formation of an elliptical shape.[1] Despite the conceptual background, there
80 is no clear evidence that LVP improves patient survival and clinical status. The STICH
81 trial, a large clinical randomized study for ischemic cardiomyopathy, showed no
82 beneficial effects of LVP in symptoms, exercise tolerance, and mortality.[2] In contrast, we
83 have reported that LVP might be effective for selective patients.[3] However, the
84 mechanism by which LVP affects biological properties in the myocardium has been
85 poorly understood.

86 A previous investigation using a rat model of LVP has shown early decreasing
87 effects of LVP on brain natriuretic peptide (BNP) gene expression.[4] However, the
88 beneficial effects of LVP did not persist; myocardial BNP increased again following LV
89 redilation late after LVP. However, the mechanism of LVP failure has not been fully
90 elucidated. In recent years, "autophagy" (self-digestion system) has received attention as
91 an important player in heart failure.

92 Myocardial autophagy has been reported to be activated in the failing heart,[5]
93 cardiac hypertrophy,[6] and myocardial infarction (MI).[7] Autophagy is an intracellular
94 degradation system, by which cytoplasmic materials, via autophagosome formation, are
95 finally digested in the lysosome.[8] There are two important roles in autophagy: recycling
96 degradation products for energy supply (amino acids and fatty acids) and control of
97 intracellular quality. After MI, autophagy has been reported to protect against progression
98 of LV dilation by increasing the energy supply to meet cellular demand in the face of

excessive wall stress and hypoxia.[7] In the present study, we hypothesised that myocardial autophagy plays an important role in LV redilation after LVP.

Methods

Experimental design

Ten-week-old male Sprague-Dawley rats weighing 300–360 g were subjected to the experimental protocol shown in **Fig. 1**. All rats were randomized into the following groups: sham (sham/sham), MI/sham, and MI/LVP. The rats in the MI/sham group underwent ligation of the left anterior descending artery (LAD) in the first operation and only underwent thoracotomy in the second operation; the rats in the MI/LVP group underwent LAD ligation in the first operation and LVP in the second operation. A 4-week period was maintained between the procedures. The animals were euthanized at 2 days ("early") or 28 days ("late") after the second operation. The mortality and number of rats are indicated in **Fig. 1**. Transthoracic echocardiography was performed at the baseline, before the second operation, and before euthanization. The heart and lung were excised and weighed at the time of euthanization. All procedures were conducted according to the Hokkaido University Manual for Implementing Animal Experimentation and were consistent with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). This study was approved by the institutional animal ethics committee.

Myocardial infarction and left ventriculoplasty

121 General anesthesia was induced by intramuscular ketamine (90 mg/kg) and xylazine (10
122 mg/kg). Following left lateral thoracotomy under ventilation, the proximal LAD was
123 ligated with 7-0 polypropylene sutures (Ethicon, Somerville, New Jersey). The MI at the
124 anterior LV wall was confirmed by akinesis through an echocardiographic examination
125 before the chest was closed. Four weeks after the LAD ligation, the rats developed a large
126 scar, but not an aneurysm, on the anterior LV wall with hypokinesis in the non-ischemic
127 lesion (**Video 1**).

128 LVP was performed as reported previously under the same anesthesia as the
129 MI.[9] Briefly, after ligation of the internal mammary arteries, a horizontal sternotomy was
130 performed at the level of the fifth intercostal space to expose the entire heart. Thereafter,
131 LVP was performed by plicating the akinetic scar area using three mattress sutures with
132 pledgetted 6-0 polypropylene (Ethicon). Much attention was paid not to stitch on the scar
133 tissue but on the viable myocardium. An over-and-over suture was then performed on the
134 plicated scar tissue (**Video 1**).

135

136 ***Transthoracic echocardiography***

137 Echocardiography was performed just before each operation and euthanization using a
138 SONOS 5500 ultrasound system with a 12-MHz phased-array transducer (Philips
139 Medical Systems, Andover, Massachusetts). After the rats were anesthetized and placed
140 in the supine position, M-mode tracings were recorded by the long-axis view of the LV
141 for the following parameters: LV end-diastolic dimension (LVDd) and end-systolic
142 dimension, fractional shortening (FS). Cardiac index (CI: cardiac output divided by body

143 weight) was measured using pulse Doppler on the LV outflow tract.

144

145 ***Catheter examination***

146 Through the right carotid artery, a 1.4-Fr micromanometer-tipped catheter (Millar,
147 Houston, Texas) was inserted into the ascending aorta and LV. The pressure data were
148 recorded using PowerLab (ADInstruments, Dunedin, NZ) and analyzed using LabChart
149 (ADInstruments). The heart rate, mean arterial blood pressure, LV end-diastolic pressure,
150 LV maximum, and minimum dPdt were measured. The time constant (Tau) was measured
151 as the time required for the pressure to decline to 50% of the value recorded at the
152 minimum dPdt.

153

154 ***Histological examination***

155 Ventricles were fixed in 10% paraformaldehyde in phosphate-buffered saline, embedded
156 in paraffin, and sectioned at 5-μm intervals. Hematoxylin-eosin staining and Masson's
157 trichrome staining were conducted using standard procedures at the mid-ventricular level.
158 The cardiomyocyte area was examined using hematoxylin-eosin-stained sections. About
159 100 randomly chosen oval-shaped cardiomyocytes with a nucleus in the septal lesion
160 (remote area) in each group were analyzed to measure the cross-sectional cardiomyocyte
161 area (μm^2) using ImageJ software (http://rsb.info.nih.gov/ij/) (NIH, Bethesda, Maryland).
162 The percentage of the fibrotic area compared to the whole tissue area was examined on
163 Masson's trichrome-stained sections. About 10 randomly chosen frames in the septal
164 lesion in each group were analyzed using ImageJ (NIH).

165

166 ***Gene expression of myosin heavy chain in the myocardium***

167 In order to assess pathological hypertrophy, gene expression of the myosin heavy chain
168 (MHC) was evaluated in each group at 28 days after the second operation. Myocardial
169 total RNA was isolated from frozen tissue samples with a High Pure RNA Tissue Kit
170 (Roche, Penzberg, Germany). The total RNA was reverse transcribed into cDNA with a
171 Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative real-time reverse
172 transcription polymerase chain reaction (RT-PCR) was performed with FastStart
173 Essential DNA Probes Master (Roche) and RealTime ready assay (Roche Assay ID,
174 501294 for *αMHC*; 500524 for *βMHC*). PCR amplification was performed in a volume
175 of 20 μL using LightCycler Nano (Roche) under the conditions suggested by the
176 manufacturer. The results were normalized to S29 transcription as a housekeeping gene,
177 which was comparable among the groups.

178

179 ***Immunoblotting of microtubule-associated protein light chain 3***

180 Myocardial autophagy was evaluated by protein expression of an autophagosome marker,
181 microtubule-associated protein light chain 3 (LC3) II. A semidry western blot apparatus
182 (Mini-PROTEAN Tetra Cell, BIO-RAD, CA, USA) was used for detecting the
183 conversion from LC3-I (cytosolic form) to LC3-II (membrane-bound lipidated form). The
184 amount of LC3-II usually correlates well with the number of autophagosomes. After
185 sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12% Mini-
186 PROTEANTGX^{TM}, BIO-RAD, CA, USA), the proteins were blotted to a polyvinyldine

187 deflouride membrane and incubated with primary (Anti-LC3B, abcam, Cambridge, UK)
188 and secondary antibodies (Anti-rabbit IgG, Cell Signaling, MA, USA). The bands were
189 semiquantified by chemiluminescence using JustTLC (Sweday, Sodra Sandby, Sweden).
190 The membranes were then dyed with naphthol blue black solution to normalize the band
191 intensity.
192
193 ***Autophagic inhibitor***
194 To examine the implications of autophagy, a PI3-kinase inhibitor (3-methyladenine: 3-
195 MA; Sigma-Aldrich, St. Louis, MO) was intraperitoneally injected at a dose of 15
196 mg/kg/day for 3 weeks before sacrifice in the MI/LVP + 3-MA group (**Fig. 1**).[10] Because
197 autophagosome formation requires class III PI3-kinase activity, PI3-kinase inhibitors are
198 the most commonly used pharmacological approach to inhibit autophagy.
199
200 ***Statistical analysis***
201 All data are presented as median (interquartile range) for continuous variables. Statistical
202 analysis was performed using non-parametric tests i.e. the Wilcoxon rank sum test,
203 Kruskal-Wallis test, and Friedman's test. The Bonferroni correction was used for post hoc
204 analysis. The differences were considered statistically significant at a value of $P < 0.05$.
205 A post hoc power analysis was conducted using *G*Power*: assuming a 5% significance
206 level and a two-sided test, the sample size had 99% power to detect effect size (r) of 0.77
207 and 0.82 (>0.5: large effect) between 2 days and 28 days for LVDd and LC3II,
208 respectively. Statistical analysis was performed using JMP Pro version 14.0 software

209 (SAS Institute Inc., Cary, NC) and SPSS version 17.0 software (SPSS Inc. Chicago, Ill).

210

211 **Results**

212 ***Protein expression of LC3-II, an autophagosome marker***

213 **Fig. 2** shows the protein expression of the autophagosome marker LC3-II, early and late
214 after LVP. In the MI/LVP group, LC3-II expression was lower than that in the MI/sham
215 group in the early phase. The reduced LC3-II expression then increased late after LVP,
216 whereas LC3-II did not change significantly from the early to late period in the MI/sham
217 group. The increased LC3-II expression was reduced by the autophagic inhibitor, 3-MA.

218

219 ***Cardiac functional parameters***

220 **Fig. 3** shows LVDd and FS in the early and late phases after LVP. In the MI/LVP group,
221 LVDd was smaller early after LVP than in the MI/sham group, which then increased late
222 after LVP. The MI/LVP+3-MA group exhibited LV redilation which was the same as in
223 the MI/sham group (**Fig. 3A**). FS was greater in the MI/LVP group than in the MI/sham
224 group early after LVP, which then decreased late after LVP. In the MI/LVP+3-MA group,
225 FS further decreased late after LVP (**Fig. 3B**). CI was not different between the MI/LVP
226 and MI/sham groups early and late after LVP**,** whereas it was decreased only in the
227 MI/LVP+3-MA group ($p<0.01$).

228 **Table 1** shows the cardiac functional parameters by Millar catheter early and
229 late after LVP. In both the MI/sham and MI/LVP groups, the maximum dPdt was smaller
230 than that in the sham group. The LV end-diastolic pressure and Tau were higher in the

231 MI/sham and MI/LVP + 3-MA groups than those in the sham group, but not in the MI/LVP
232 group late after LVP. From the early to late phase, the LV end-diastolic pressure and Tau
233 increased only in the MI/LVP+3-MA group.
234
235 ***Histological examination***
236 **Fig. 4** shows the cardiomyocyte area and myocardial fibrosis determined by histological
237 examination. In the MI/LVP group, the cardiomyocyte area was smaller than that in the
238 MI/sham group in the late period. However, the myocyte area increased from the early to
239 late stage after LVP. In the MI/LVP+3-MA group, myocyte area increased to the same
240 degree as that in the MI/sham group (**Fig. 4B**). There was no significant difference in
241 fibrosis among the MI groups (**Fig. 4D**).
242
243 ***Gene expression of myosin heavy chain in the myocardium***
244 Though there was no significant difference in the gene expression of *αMHC* and *βMHC*
245 among the groups, the *α/β MHC* ratio, a lower value of which indicates a relative increase
246 in fetal gene, was significantly smaller in the MI/LVP+3-MA than in the MI/sham group
247 (**Fig. 5**).
248
249 ***Body, heart, and lung weights early and late after LVP***
250 **Table 2** shows the body, heart, and lung weights early and late after LVP. The heart
251 weights in the MI/LVP groups were excluded from the analysis due to presence of
252 pledgets and additional scar tissue. Lung/body weight ratio in the late phase was greater

253 only in the MI/sham and MI/LVP+3-MA groups than in the sham group.

254

255 **Discussion**

256 We demonstrated here that in a rat model of MI, myocardial autophagy decreased early
257 after LVP and increased again during LV redilation. Because pharmacological inhibition
258 of autophagy exaggerated the LV redilation, autophagy may play an important role in LV
259 redilation after LVP.

260

261 ***Pathology after MI in rats and humans***

262 There are several differences in myocardial pathology after MI between rats and humans.
263 First, the septal region is intact after ligation of LAD in rats because of good collaterals
264 from the right coronary system,[11] whereas both septum and free wall are usually affected
265 in humans. The risk area might be smaller in rats than in humans, which would influence
266 later LV remodeling and hypertrophy. Second, the distribution of the *MHC* isoforms is
267 different: *αMHC* is the predominant isoform in the rat ventricle, whereas *βMHC*
268 predominates in the human ventricle. Although the change in *MHC* gene expression
269 would be different between the species, the decrease in the α and β ratio in pathological
270 hypertrophy is consistent.[12] Myocyte hypertrophy seen in this model has been also found
271 in human studies late after MI.[11]

272

273 ***Differences in surgical techniques: Plication vs. excision of scar area***

274 In the current study, we performed LVP by plication of the akinetic scar area. In such a

275 small animal model, we cannot perform LVP to restore ventricular geometry by
276 endoventricular patch plasty using cardiopulmonary bypass system (eg. Dor procedure in
277 STICH trial). This plication technique might have induced too small an LV cavity. The
278 LV volume was reduced by over 50% after LVP. In previous clinical studies, desired LV
279 volume reduction ratio after LVP was more than 30-33%,[13,14] whereas in the STICH trial,
280 the ratio was 19%.[2] Nonetheless, the drawback of the plication technique of the entire
281 scar is that it is not possible to control the residual LV volume during surgery. Our model
282 would be analogous to a recently developed less invasive LVP devise (Revivent TC
283 system).[15] In both our model and the Revivent TC system, the LV anterior akinetic area
284 can be excluded by linear plication. Moreover, both techniques do not require
285 cardiopulmonary bypass, cardioplegic arrest, or a ventriculotomy.
286
287 ***Myocardial autophagy and left ventricular unloading***
288 Myocardial autophagy has been reported to be activated in the failing heart,[5] cardiac
289 hypertrophy,[6] and ischemic heart disease.[16] Whether myocardial autophagy can be
290 "adaptive" or "maladaptive" depends on the pathology and stages of disease. Kassiotis
291 and colleagues reported that in patients with advanced heart failure, mechanical
292 unloading with a left ventricular assist device reduced the activation of autophagy.[17] They
293 therefore insisted that autophagy might be adaptive in the failing heart.
294 In our recent study, reduction of LC3-II observed early after LVP may be related to
295 the LV unloading by LVP. On the contrary, late after LVP, the reduced LC3-II expression
296 was increased again, and was parallel to the LV redilation. We also showed that the

297 pharmacological inhibition of late autophagy exaggerated the pathological LV
298 hypertrophy and redilation. We thus speculate that LV unloading by LVP attenuates the
299 demand for myocardial hypertrophy and autophagy activation; however, late LV
300 redilation increases myocardial hypertrophy and triggers the reactivation of autophagy.
301 We therefore argue that myocardial autophagy may play an adaptive role in LV redilation
302 after LVP.
303
304 ***Limitations***
305 This study has some limitations. First, autophagic flux was not examined in the recent
306 study. Second, the animals were not administered any guideline-directed medicines.
307 Carvedilol, for instance, can also enhance autophagy in a rat model of MI.[18] Thus, the
308 current results cannot be directly applied to clinical practice in humans. Third, 3-MA has
309 several off-target effects; it can inhibit not only class III but also class I PI3K. Class I
310 PI3K is mainly activated via the insulin receptor, leading to AKT activation.[19] Thus, the
311 3-MA-mediated inhibition of class I PI3K might influence insulin signaling. Insulin
312 resistance is also one of the causes for myocyte hypertrophy and dysfunction. As 3-MA
313 was used 5 weeks after MI in the present study, it may not have influenced infarct size.
314 Nonetheless, we cannot exclude the negative off-target effects of 3-MA on myocardial
315 metabolism in the later phase. Concomitant use of wortmannin, another PI3K inhibitor,
316 should be considered in future studies. Forth, there would be selection bias because of the
317 high mortality especially after LVP; it is possible that autophagic activation was different
318 between the examined and dead animals after LVP.

Conclusions

In a rat model of MI, myocardial autophagy decreased early after LVP and increased during LV redilation late after LVP. Although the animal model does not replicate clinical pathogenesis, autophagy may play an important role in LV redilation after LVP.

Acknowledgments

We wish to thank Philips Electronics Japan for technical support in echocardiography and Sapporo Medical Corporation for technical support in catheter examination. We would like to thank Editage for English language editing.

328 **References**

329 1. Matsui Y. Overlapping Left Ventricular Restoration. *Circ J*. 2009;Suppl A:13-
330 18.
331 2. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al.
332 Coronary bypass surgery with or without surgical ventricular reconstruction. *N*
333 *Engl J Med*. 2009;360:1705-1717.
334 3. Wakasa S, Matsui Y, Kobayashi J, Cho Y, Yaku H, Matsumiya G, et al.
335 Estimating postoperative left ventricular volume : Identification of responders to
336 surgical ventricular reconstruction. *J Thorac Cardiovasc Surg*. 2018;156:2088-
337 2096.
338 4. Nishina T, Nishimura K, Yuasa S, Senri M, Nomoto T, Sakakibara Y, et al.
339 Initial Effects of the Left Ventricular Repair by Plication May Not Last Long in a
340 Rat Ischemic Cardiomyopathy Model. *Circulation*. 2001;104(suppl 1):I-241-I-
341 245.
342 5. Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H.
343 Autophagic degeneration and death of cardiomyocytes in heart failure.
344 *Autophagy*. 2006;2(3):212-214.
345 6. Elsässer A, Arnon E, Kostin S, Hein S, Schaper J, Bauer EP, et al. Progression
346 From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human
347 Heart. *Circulation*. 2003;107(7):984-991.
348 7. Kanamori H, Takemura G, Goto K, Maruyama R, Tsujimoto A, Ogino A, et al.
349 The role of autophagy emerging in postinfarction cardiac remodelling.

350 *Cardiovasc Res*. 2011;91(2):330-339.

351 8. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. *Cell*.
352 2011;147(4):728-741.

353 9. Asai H, Shingu Y, Yamakawa T, Niwano H, Wakasa S, Ooka T, et al. Left-
354 Ventricular Plication Reduces Wall Stress and Cardiomyocyte Hypertrophy in a
355 Rat Model of Ischemic Cardiomyopathy. *Eur Surg Res*. 2017;58(1-2):69-80.

356 10. Maeda H, Nagai H, Takemura G, Shintani-Ishida K, Komatsu M, Ogura S, et al.
357 Intermittent-hypoxia induced autophagy attenuates contractile dysfunction and
358 myocardial injury in rat heart. *Biochim Biophys Acta - Mol Basis Dis*.
359 2013;1832(8):1159-1166.

360 11. Olivetti G, Quaini F, Lagrasta C, Cigola E, Ricci R, Maestri R, et al. Cellular
361 basis of ventricular remodeling after myocardial infarction in rats. *Am J Cardiol*.
362 1991;68:7-16.

363 12. Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac
364 function during stress. *J Am Coll Cardiol*. 2004;44(12):2390-2397.

365 13. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM,
366 et al. Insights from the STICH trial: Change in left ventricular size after coronary
367 artery bypass grafting with and without surgical ventricular reconstruction. *J*
368 *Thorac Cardiovasc Surg*. 2013;146(5):1139-1145.e6.

369 14. Isomura T, Hoshino J, Fukada Y, Kitamura A, Katahira S, Kondo T, et al.
370 Volume reduction rate by surgical ventricular restoration determines late
371 outcome in ischaemic cardiomyopathy. *Eur J Heart Fail*. 2011;13(4):423-431.

372 15. Chiariello GA, Nesta M, Bruno P, Pasquini A, Ferraro F, Cammertoni F, Marano
373 R, Colizzi C, Farina P, D'Amario D, Trani C MM. Total Surgical Plication of
374 Left Ventricular Aneurysm Using the BioVentrixRevivent Myocardial
375 Anchoring System. *Innovations*. 2019;14(4):369-373.
376 16. Kim S-J, Matsui Y, Yan L, Ge H, Vatner SF, Masurekar M, et al. Autophagy in
377 chronically ischemic myocardium. *Proc Natl Acad Sci*. 2005;102(39):13807-
378 13812.
379 17. Kassiotis C, Bailai K, Wellnitz K, Vela D, Gong M, Salazar RS, et al. Markers of
380 autophagy are downregulated in failing human heart after mechanical unloading.
381 *Circulation*. 2009;120(SUPPL. 1):191-198.
382 18. Zhang JL, Lu JK, Chen D, Cai Q, Li TX, Wu LS WX. Myocardial autophagy
383 variation during acute myocardial infarction in rats: the effects of carvedilol.
384 *Chin Med J (Engl)*. 2009;122(19):2372-2379.
385 19. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, et al. Dual role of 3-
386 methyladenine in modulation of autophagy via different temporal patterns of
387 inhibition on class I and III phosphoinositide 3-kinase. *J Biol Chem*.
388 2010;285(14):10850-10861.
389

390 **Figure legends**

391 **Figure 1.** Experimental protocol. We performed MI for 170 rats, and 54 rats died after
392 MI (mortality, 32%). Of the remaining 116 rats, 25 and 91 were categorized into the
393 MI/sham and MI/LVP groups, respectively. In the MI/LVP group, 50 rats were lost after
394 LVP (mortality, 55%). Three additional rats died during the period of 3-MA injection.
395 LVP, left ventriculoplasty; 3-MA, 3-methyladenine; MI, myocardial infarction; TTE,
396 transthoracic echocardiography.

397

398 **Figure 2.** Protein expression of LC3-II, an autophagosome marker, early (2-day group)
399 and late (28-day group) after LVP. (A) representative bands; (B) normalized band analysis.
400 The upper and lower borders of the box represent the upper and lower quartiles,
401 respectively. The middle horizontal line represents the median. The upper and lower
402 whiskers represent the maximum and minimum values of non-outliers, respectively. The
403 P values are Bonferroni-adjusted. * $p < 0.05$, ** $p < 0.01$; $^{\#}$ $p < 0.05$, $^{\#\#}$ $p < 0.01$ *vs.* 2 days.
404 LC3, microtubule-associated protein light chain 3, LVP, left ventriculoplasty; 3-MA, 3-
405 methyladenine; MI, myocardial infarction.

406

407 **Figure 3.** Serial changes in echocardiographic parameters early (2-day group) and late
408 (28-day group) after LVP: LVDd (A), FS (B). The time points of measurements were day
409 0, 28, 30 in the 2-day group and day 0, 28, 56 in the 28-day group. The upper and lower
410 borders of the box represent the upper and lower quartiles, respectively. The middle
411 horizontal line represents the median. The upper and lower whiskers represent the

412 maximum and minimum values of non-outliers, respectively. The P values are
413 Bonferroni-adjusted. *p < 0.05, ** p < 0.01; # p < 0.05, ## p < 0.01 *vs*. 2-day group; † p <
414 0.05, †† p < 0.01 *vs*. day 0; $ p < 0.05 *vs*. day 28. FS, fractional shortening; LVDd, left
415 ventricular end-diastolic dimension; LVP, left ventriculoplasty; 3-MA, 3-methyladenine;
416 MI, myocardial infarction.
417
418 **Figure 4.** Cardiomyocyte hypertrophy and myocardial fibrosis. (A) Representative
419 photomicrographs of hematoxylin-eosin-stained sections in the septal lesion. (B)
420 Cardiomyocyte area in each group. (C) Representative photomicrographs of Masson's
421 trichrome-stained sections in the septal lesion. (D) Myocardial fibrosis in each group.
422 Scale bars in A and C: 50 μm. The upper and lower borders of the box represent the upper
423 and lower quartiles, respectively. The middle horizontal line represents the median. The
424 upper and lower whiskers represent the maximum and minimum values of non-outliers,
425 respectively. The P values are Bonferroni-adjusted. * p < 0.05, ** p < 0.01; # p < 0.05, ##
426 p < 0.01 *vs*. 2 days. LVP, left ventriculoplasty; 3-MA, 3-methyladenine; MI, myocardial
427 infarction.
428
429 **Figure 5.** *α/β MHC* ratio late after LVP. The upper and lower borders of the box represent
430 the upper and lower quartiles, respectively. The middle horizontal line represents the
431 median. The upper and lower whiskers represent the maximum and minimum values of
432 non-outliers, respectively. The P values are Bonferroni-adjusted. * p < 0.05. LVP, left
433 ventriculoplasty; 3-MA, 3-methyladenine; MHC, myosin heavy chain; MI, myocardial

infarction.

Figure 6 (graphical abstract).

Myocardial autophagy decreased early after LV plasty and increased during LV redilation late after LV plasty, which might be one of the mechanisms of late LV redilation. LV, left ventricle; 3-MA, 3-methyladenine; MI, myocardial infarction.

Video legend

Video 1. Surgical procedures of MI and LVP. LAD, left anterior descending artery; LVP, left ventriculoplasty; MI, myocardial infarction.

Table 1. Cardiac functional parameters by Millar catheter early and late after LVP

	2-day group			28-day group			
	sham n=9	MI/sham n=12	MI/LVP n=11	sham n=6	MI/sham n=13	MI/LVP n=17	MI/LVP + 3MA n=10
Heart rate (bpm)	270 (218-316)	291 (270-323)	318 (295-345)	279 (247-310)	243 (234-259)	263 (239-339)	232 (230-238)
mABP (mmHg)	77 (72-86)	80 (75-92)	80 (69-87)	100## (93-102)	92# (85-98)	84* (78-88)	84 (60-85)
LV developed pressure (mmHg)	102 (94-116)	95 (88-101)	97 (91-101)	123# (112-123)	99 (91-112)	95 (89-105)	88 (72-89)
max dp/dt (mmHg/s)	8360 (7046-9552)	6371 (5367-6747)	6649 (6030-7182)	10133 (8491-11397)	6510* (5579-7391)	7123* (5992-8029)	5972 (3318-6306)
min -dp/dt (mmHg/s)	6128 (4423-7014)	4403 (4250-5129)	4322 (3601-4709)	6076 (5312-6839)	3884 (3075-4463)	4083 (3349-5054)	3184# (3079-3195)
LVEDP (mmHg)	-2.3 (-8.1-2.2)	6.3 (2.4-9.6)	1.0 (-1.3-6.6)	0.2 (-0.8-1.0)	14.7# ** (6.4-17.7)	5.2 (2.1-20.0)	12.2# * (5.7-22.0)
Tau (ms)	7.4 (6.5-8.8)	9.3 (8.5-12.4)	8.3 (6.8-9.6)	7.6 (7.3-7.8)	11.3* (9.8-14.1)	8.9 (8.3-10.9)	13.4## * (12.5-14.4)

Values are median (first quartile – third quartile). LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; LVP, left ventriculoplasty; 3-MA, 3-methyladenine; mABP, mean aortic pressure; MI, myocardial infarction. The P values are Bonferroni-adjusted. *p<0.05 vs sham; ** p<0.01 vs sham; # p<0.05 vs 2-day group; ## p<0.01 vs 2-day group.

Table 2. Body, heart, and lung weights early and late after LVP

	2-day group			28-day group			
	sham n=9	MI/sham n=12	MI/LVP n=10	sham n=6	MI/sham n=13	MI/LVP n=17	MI/LVP + 3MA n=10
Body weight (g)	449 (425-463)	397* (384-400)	376** (354-412)	520# (503-538)	460## (445-500)	480## (430-520)	445# (423-485)
Heart weight (mg)	1223 (1119-1306)	1336* (1278-1500)	NA	1539## (1466-1632)	1732 (1464-1976)	NA	NA
Heart /body weight (mg/g)	2.7 (2.6-2.8)	3.4** (3.2-3.6)	NA	3.1 (3.0-3.2)	3.5 (3.1-4.1)	NA	NA
Atrial weight (mg)	155 (149-174)	184 (175-260)	276** (236-357)	255# (219-267)	327 (206-530)	256 (200-500)	461 (264-662)
Atrial/body weight (mg/g)	0.33 (0.33-0.37)	0.46** (0.46-0.65)	0.76** (0.57-0.92)	0.52 (0.39-0.57)	0.65 (0.48-1.07)	0.57 (0.39-0.99)	1.07 (0.66-1.47)
Lung weight (mg)	1478 (1447-1515)	1531 (1397-1989)	2171* (1701-2921)	1661## (1598-1681)	2305* (2008-2939)	1888 (1692-2585)	2239** (2034-3279)
Lung/body weight (mg/g)	3.3 (3.2-3.5)	3.9** (3.6-5.0)	6.0** (4.0-7.8)	3.1 (3.1-3.2)	5.1* (4.4-6.5)	3.9 (3.5-5.1)	5.6** (4.6-7.1)

Values are median (first quartile – third quartile). NA, not applicable; LVP, left ventriculoplasty; 3-MA, 3-methyladenine; MI, myocardial infarction.
The P values are Bonferroni-adjusted. * $p<0.05$ vs sham; ** $p<0.01$ vs sham; # $p<0.05$ vs 2-day group; ## $p<0.01$ vs 2-day group.


day 0
28
30
56
1st OP
2nd OP
Sacrifice
Sacrifice
28 days
2days
28days
sham
n=15
sham
n=15
n=9
n=6
sham
sham
n=25
n=12
n=13
MI / sham
MI
n=170
LVP
n=91
n=11
n=17
MI / LVP
dead
n=54
dead
n=50
21 days
3-MA i.p.
n=10
MI / LVP + 3-MA
dead
n=3
TTE
TTE
TTE
Catheter
TTE
Catheter


A
LC3 I
LC3 II
sham
MI/sham
MI/LVP
LC3 I
LC3 II
sham
MI/sham
MI/LVP
MI/LVP+3MA
B
2-days after 2nd OP
28-days after 2nd OP
LC3II (arbitary unit)
0
1
2
3
4
5
6
7
*
**
*
*
*
##
##
#
n=3
n=5
n=6
n=6
n=9
n=9
n=10
sham
MI/sham
MI/LVP
sham
MI/sham
MI/LVP
MI/LVP+3MA


2-day group
28-day group
A
day
0 28 30
0 28 56
LVDd (mm)
n=9
n=12
n=11
n=6
n=13
n=17
n=10
sham
MI/sham
MI/LVP
MI/LVP+3MA
P=0.06
B
FS (%)
P=0.08


A
2-days
sham
MI/sham
MI/LVP
28-days
sham
MI/sham
MI/LVP
MI/LVP+3MA
C
2-days
sham
MI/sham
MI/LVP
28-days
sham
MI/sham
MI/LVP
MI/LVP+3MA
B
2-days after 2nd OP
28-days after 2nd OP
Myocyte area (μm2)
900
800
700
600
500
400
300
*
**
#
##
n=6
n=10
n=5
n=9
n=11
n=7
sham
MI/sham
MI/LVP
MI/LVP+3MA
D
2-days after 2nd OP
28-days after 2nd OP
Fibrotic area (%)
3.0
2.5
2.0
1.5
1.0
0.5
0.0

28-days after 2nd OP




day 0
28
30
56
MI in rats
n=170
sham
n=25
autophagy
n=12
LV plasty
n=91
n=11
autophagy
LV redilation
n=13
n=17
pharmacological
autophagy inhibition (3-MA)
n=10
mechanism of
LV redilation
after LV plasty
"autophagy"
LV redilation
after LV plasty